Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naive type 2 diabetes: Design and population

被引:11
|
作者
Bonadonna, R. C. [1 ]
Giaccari, A. [2 ,3 ]
Buzzetti, R. [4 ]
Aimaretti, G. [5 ]
Cucinotta, D. [6 ]
Avogaro, A. [7 ]
Perseghin, G. [8 ]
Larosa, M. [9 ]
Bolli, G. B. [10 ]
Fanelli, C. G. [10 ]
机构
[1] Univ Parma, Div Endocrinol & Metab Dis, Dept Med & Surg, AOU Parma, Via Gramsci 14, I-43126 Parma, Italy
[2] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy
[3] Univ Cattolica Sacro Cuore, Rome, Italy
[4] Sapienza Univ Rome, Rome, RM, Italy
[5] Univ Eastern Piedmt, Vercelli, VC, Italy
[6] Univ Messina, Messina, Italy
[7] Univ Padua, Padua, Italy
[8] Univ Milano Bicocca, Milan, MI, Italy
[9] Sanofi, Milan, Italy
[10] Perugia Univ, Sect Endocrinol & Metab, Dept Med, Med Sch, Perugia, Italy
关键词
Type; 2; diabetes; Insulin glargine 300 U/mL; Patient empowerment; Insulin titration; GLYCEMIC CONTROL; CLINICAL INERTIA; PEOPLE; INTENSIFICATION; HYPOGLYCEMIA; INITIATION; BARRIERS;
D O I
10.1016/j.numecd.2019.01.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: Fostering patient's self-managing of basal insulin therapy could improve glucose control, by removing patient's and physician's barriers to basal insulin initiation, titration and glucose monitoring. The Italian Titration Approaches Study (ITAS) aims at demonstrating non-inferiority (<0.3% margin) in efficacy of glucose control (change in glycated hemoglobin [HbA1c] after 24 weeks) by the same titration algorithm of insulin glargine 300 U/mL (Gla-300), managed by the (nurse assisted) patient versus the physician, in insulin naive patients with Type 2 Diabetes Mellitus (T2DM), uncontrolled with previous treatments. Methods and results: ITAS is a phase IV, 24-week, national, multicenter, open label, randomized (1:1) parallel group study. 458 patients were enrolled, 359 randomized, and 339 completed the study, in 46 Italian centers. Baseline characteristics and previous medications of the ITT population (N = 355) are reported. Mean +/- SD age, T2DM duration, HbA1c, FPG and BMI were 64.0 +/- 9.8 years, 11.6 +/- 7.6 years, 8.79 +/- 0.65%, 170.9 +/- 42.3 mg/dL, and 30.3 +/- 5.6 kg/m(2) , respectively. Vascular and metabolic disorders were most frequent (73.8% and 58.3%, respectively). More than 90% of patients were on metformin. Conclusion: ITAS is the first study to compare two different managers (nurse-assisted patient vs physician) of the same titration algorithm of Gla-300 in insulin naive patients with T2DM in unsatisfactory glucose control. This study might provide novel evidence on the efficacy/ Acronyms: effectiveness of patient-managed titration algorithm of Gla-300 in a pragmatic setting and may reduce barriers to basal insulin initiation and its titration. (C) 2019 Published by Elsevier B.V. on behalf of The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University.
引用
收藏
页码:496 / 503
页数:8
相关论文
共 50 条
  • [31] ATOS: REAL-WORLD EFFECTIVENESS AND SAFETY OF INSULIN GLARGINE 300 U/ML IN INSULIN-NAIVE PEOPLE WITH TYPE 2 DIABETES: AD-HOC ANALYSIS OF RUSSIAN POPULATION.
    Galstyan, G.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A98 - A99
  • [32] Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naive Patients with Type 2 Diabetes Mellitus: DosInGlar Study
    Duque, Natalia
    Artime, Esther
    Romera, Irene
    Lebrec, Jeremie
    Diaz, Silvia
    Rubio, Miriam
    Sicras-Mainar, Antoni
    Carretero-Anibarro, Enrique
    Mundet, Xavier
    Gorgojo-Martinez, Juan J.
    Reviriego, Jesus
    ADVANCES IN THERAPY, 2021, 38 (07) : 3857 - 3871
  • [33] Real-world effectiveness and safety of insulin glargine 300 U/ml in insulin-naive people with type 2 diabetes in the Latin America region: A subgroup analysis of the ATOS
    Vargas-Uricoechea, Hernando
    Burga Nunez, Jose Luis
    Rosas Guzman, Juan
    Silva-Gomez, Liliana
    Beltran, Sergio
    Sanudo-Maury, Maria Elena
    DIABETES OBESITY & METABOLISM, 2023, 25 (01): : 238 - 247
  • [34] Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
    Lau, Ip Tim
    Lee, Ka Fai
    So, Wing Yee
    Tan, Kathryn
    Yeung, Vincent Tok Fai
    DIABETES METABOLIC SYNDROME AND OBESITY, 2017, 10 : 273 - 284
  • [35] Glycaemic variability and risk for hypoglycaemia on insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes
    Kovatchev, B.
    Meng, Z.
    Breton, M.
    Leroy, B.
    Cali, A.
    Perfetti, R.
    DIABETOLOGIA, 2017, 60 : S36 - S37
  • [36] Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (gla-300) in Insulin-Naive Patients with Type 2 Diabetes (T2DM): Interim Analysis of the ATOS Study
    Galstyan, Gagik R.
    Bhansali, Anil
    Vargas-Uricoechea, Hernando
    Tirosh, Amir
    Sun, Guannan
    Naqvi, Mubarak
    Pilorget, Valerie
    Coudert, Mathieu
    Cherkasov, Dmitry
    Khan, Niaz
    DIABETES, 2020, 69
  • [37] Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
    Kovatchev, Boris
    Meng, Zhaoling
    Cali, Anna M. G.
    Perfetti, Riccardo
    Breton, Marc D.
    DIABETES THERAPY, 2020, 11 (06) : 1293 - 1302
  • [38] Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
    Boris Kovatchev
    Zhaoling Meng
    Anna M. G. Cali
    Riccardo Perfetti
    Marc D. Breton
    Diabetes Therapy, 2020, 11 : 1293 - 1302
  • [39] Comparative effectiveness and safety of glargine 300 U/mL versus degludec 100 U/mL in insulin-naive patients with type 2 diabetes. A multicenter retrospective real-world study (RESTORE-2 NAIVE STUDY)
    Fadini, Gian Paolo
    Buzzetti, Raffaella
    Nicolucci, Antonio
    Larosa, Monica
    Rossi, Maria Chiara
    Cucinotta, Domenico
    ACTA DIABETOLOGICA, 2022, 59 (10) : 1317 - 1330
  • [40] GLYCAEMIC VARIABILITY AND TIME-IN-RANGE DURING SELF-TITRATION OF ONCE DAILY INSULIN GLARGINE 300U/ML VERSUS NPH (NEUTRAL PROTAMINE HAGEDORN) INSULIN IN INSULIN-NAIVE CHINESE TYPE 2 DIABETES PATIENTS
    Ling, J.
    Ozaki, R.
    Luk, A.
    Chan, J.
    Chow, E.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A23 - A24